revision accepted Mar. 24. 1998. For correspondence or reprints contact: Ado J. van
Rensburg, PhD, Department of Radiation Oncology, Private Bag X169, Pretoria, 0001, South …

Abstract 153 Sm-EDTMP (ethylenediaminetetramethylene phosphonate), prepared from a
kit, was administered to 28 patients in a clinical trial of therapy for painful skeletal …

Calculations have been undertaken to estimate the likely radiation dose received by patients
undergoing treatment with samarium-153-EDTMP. Previously known bone structure …

Skeletal retention was calculated from unnary excretion. Re suits: No uptake of 1@ Sm-
EDTMPin nonskeletaltissues was observed in whole-body gamma camera images. The …

(2, 6— 10). Rare earth isotopes all have similar chemical properties and can be
compounded with various phos phonate chelating agents to decrease their toxicity and …

A comment on this article appears in" Samarium-153-EDTMP dosimetry." J Nucl Med. 1994
Jan; 35 (1): 191-2. A comment on this article appears in" Biodistribution and dosimetry of …

Thirty-five patients with painful bone metastases arising from a variety of tumor types
underwent a clinical trial in which 153Sm-EDTMP was injected as a single intravenous …

MATERIALSAND METHODS Forty dogs with a variety ofskeletal neoplasias were treated
with †53Sm-EDTMP (Table 1). The dogs (21 male and 19 female) ranged in age from 18 …

EDTMP in the human body is derived from experimental biodistributions of activity in rats as
a function of time postinjection [pi](3). A summary of animal distribution data is given in Table …

Objective To evaluate the measurement of Samarium-153 ethylenediaminetetramethylene
phosphonic acid (153Sm-EDTMP) bone uptake rate using whole-body scintigraphy and …